Related Experiment Videos
New drugs for the treatment of sarcomas
1Department of Medical Oncology, University Hospital of Antwerp, Belgium.
Abstract:
Despite the fact that many new active drugs recently became available for phase II studies of the different sarcoma types, only soft tissue sarcoma has been included in these phase II testing programs. The groups active in the treatment of osteosarcomas and Ewing's sarcomas should be encouraged to investigate the new active drugs in the relapsing patients. For soft tissue sarcoma, many new drugs have been tested by different groups. The results to date have been disappointing, because only docetaxel has been identified as a new active drug in one phase II study. Hints of activity have also been observed for edatrexate and topotecan. Further studies with these three drugs are necessary to identify their proper role.
Insights
New active drugs are being investigated for various sarcoma types. While soft tissue sarcoma trials show limited success with docetaxel, further research is needed for edatrexate and topotecan in relapsing patients.
Area of Science:
- Oncology
- Pharmacology
Background:
- Many novel active drugs are available for phase II studies across different sarcoma subtypes.
- Currently, only soft tissue sarcoma is being evaluated in these phase II testing programs.
Purpose of the Study:
- To assess the efficacy of new drugs in phase II studies for various sarcoma types.
- To encourage investigation of new active drugs in relapsing osteosarcomas and Ewing's sarcomas.
- To identify the role of docetaxel, edatrexate, and topotecan in soft tissue sarcoma treatment.
Main Methods:
- Phase II clinical studies were conducted for various sarcoma types.
- Drug efficacy was evaluated in patients with relapsing osteosarcomas and Ewing's sarcomas.
- Specific focus on soft tissue sarcoma drug testing.
Main Results:
- Disappointing results in soft tissue sarcoma trials, with only docetaxel showing activity in one phase II study.
- Edatrexate and topotecan demonstrated preliminary signs of activity in soft tissue sarcoma.
- Limited investigation of new drugs in osteosarcomas and Ewing's sarcomas.
Conclusions:
- Further phase II studies are essential for docetaxel, edatrexate, and topotecan in soft tissue sarcoma.
- Encouragement is needed for groups treating osteosarcomas and Ewing's sarcomas to explore new drugs in relapsing cases.